SCHEMBL23364774

SCHEMBL23364774

NCC1(O)CCC(OCc2ccccc2)C1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.61
OPRM1 P35372 2/20 0.50
OPRL1 P41146 2/20 0.50
SIGMAR1 Q99720 2/20 0.42
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSK P43235 1/20 0.41
EPHX2 P34913 1/20 0.41
TMEM97 Q5BJF2 1/20 0.39
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
PRMT8 Q9NR22 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
HDAC4 P56524 1/20 0.36
BCHE P06276 1/20 0.36
AGTR2 P50052 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14451368 0.91 DPP4 (0.68) DPP4OPRM1OPRL1SIGMAR1CTSL
Hydrochloric Acid SCHEMBL5514632 0.89 DPP4 (0.67) DPP4OPRM1OPRL1SIGMAR1CTSL
Hydrochloric Acid SCHEMBL5722088 0.84 DPP4 (0.56) DPP4OPRM1OPRL1SIGMAR1CTSL
SCHEMBL14602694 0.81 OPRM1 (0.47) DPP4OPRM1OPRL1SIGMAR1CTSL
SCHEMBL13345971 0.81 OPRM1 (0.47) DPP4OPRM1OPRL1SIGMAR1CTSL
SCHEMBL11945826 0.80 OPRM1 (0.55) DPP4OPRM1OPRL1SIGMAR1CTSL
SCHEMBL23380038 0.78 DPP4 (0.49) DPP4OPRM1OPRL1SIGMAR1CTSL
SCHEMBL20621138 0.78 CTSL (0.45) DPP4OPRM1OPRL1SIGMAR1CTSL
SCHEMBL8586277 0.77 DPP4 (0.51) DPP4OPRM1OPRL1SIGMAR1CTSL
SCHEMBL23010798 0.76 PRMT3 (0.44) DPP4CARM1PRMT6PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025129104-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS INC. (US) 2025-06-19 WO disclosed
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION 2024-01-04 US disclosed
EP-4058439-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY Genzyme Corporation (US) 2022-09-21 EP disclosed
CN-115003659-A 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity 健赞公司 2022-09-02 CN disclosed
WO-2021097057-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY CFTR, PKD2, PKD1 DPP4 2120/4885OPRM1 4379/4885OPRL1 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.